The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of neoadjuvant chemoradiation (CRT) plus sorafenib (S) for high-risk extremity soft tissue sarcomas (STS).
Janelle Marie Meyer
No relevant relationships to disclose
Kelly Shea Perlewitz
No relevant relationships to disclose
James B. Hayden
No relevant relationships to disclose
Arthur Hung
No relevant relationships to disclose
Yee-Cheen Doung
No relevant relationships to disclose
Atiya Mansoor
No relevant relationships to disclose
Brooke Beckett
No relevant relationships to disclose
Megan L. Holtorf
No relevant relationships to disclose
William J. Woodward
No relevant relationships to disclose
Eve T. Rodler
Research Funding - Abbott Laboratories
Robin Lewis Jones
No relevant relationships to disclose
Wei Huang
Consultant or Advisory Role - DeltaPoint (U)
Research Funding - NIH
Christopher W. Ryan
Consultant or Advisory Role - Bayer; Onyx
Honoraria - Onyx
Research Funding - Bayer; Onyx